Drugmakers collaborate to overcome obstacles in R&D

Abbott Laboratories, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche Holding unit Genentech and Sanofi will contribute financial resources and personnel to the TransCelerate Biopharma project to overcome inefficiency in drug development. The collaboration's initial focus is streamlining and standardizing clinical trials. "This collaborative approach in the precompetitive arena, utilizing the collective experience and resources of 10 leading drug companies and others to follow, has the promise to lead to new paradigms and cost savings in drug development," FDA Center for Drug Evaluation and Research Director Dr. Janet Woodcock said.

View Full Article in:

New York Times (tiered subscription model), The · Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
PacificSource
Springfield, OR
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA